A new study finds that the cancer drug imatinib does not lower Aβ in humans, casting doubt on a previously described relationship between imatinib, γ-secretase activating protein (GSAP), and Aβ.
Antibodies against extracellular tau block seeding, diminish brain pathology, and may improve cognition in a mouse model.
Alzheimer's disease researchers expressed sadness this week at the sudden death of Larry Sparks...
A newly discovered lipid modification on the amyloid precursor protein may mark it for amyloidogenic processing...
Known for his contributions to the fundamental understanding of the tau protein, Skip Binder leaves his mark on the Alzheimer's field.
A drug candidate for Alzheimer’s aims to make cell trafficking more efficient, reduce Aβ production.
IMAGINE that: Amyloid deposition shrinks in both treatment and placebo groups, dealing a blow to the anti-aggregation drug PBT2.
The insoluble proteome from Alzheimer’s brains points to RNA processing proteins as a novel component of aggregates.
The NIH announced $45 million in new funding to support trials in preclinical Alzheimer’s populations, as well as efforts to identify new therapeutic targets.
A Phase 2 trial suggests that the drug PBT2 is generally safe for Huntington’s patients. The drug's sponsor says it may have improved cognition, though experts remain unconvinced.
Scientists report that endocytosis whisks α-secretase away from the cell membrane in a process that seems regulated by neuronal activity...
Researchers reported in 2012 that the cancer drug bexarotene swiftly cleared amyloid-β and restored memory in transgenic mouse models of Alzheimer's disease...
The latest data on TREM2 confirm that a variant in the gene associates with AD, and link it to Parkinson’s, brain degeneration, and γ-secretase.
At AAIC 2013, researchers present the latest genetic risk factors for Alzheimer's disease.
It’s a scenario familiar to many clinicians: A patient diagnosed with mild cognitive impairment asks if he or she will eventually develop Alzheimer’s disease.